Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Investment analysts at Zacks Research issued their FY2027 earnings per share estimates for shares of Blueprint Medicines in a research report issued on Wednesday, March 5th. Zacks Research analyst A. Chakraborty forecasts that the biotechnology company will post earnings of $3.20 per share for the year. The consensus estimate for Blueprint Medicines' current full-year earnings is ($1.28) per share.
A number of other equities analysts have also weighed in on the company. StockNews.com lowered Blueprint Medicines from a "hold" rating to a "sell" rating in a research note on Monday, March 3rd. Guggenheim restated a "buy" rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. Wedbush restated an "outperform" rating and set a $128.00 target price on shares of Blueprint Medicines in a report on Friday, February 28th. Needham & Company LLC restated a "buy" rating and set a $133.00 price objective on shares of Blueprint Medicines in a research report on Thursday, February 13th. Finally, Stephens reissued an "overweight" rating and set a $140.00 price objective on shares of Blueprint Medicines in a research report on Thursday, January 2nd. Two research analysts have rated the stock with a sell rating, six have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $125.21.
Check Out Our Latest Stock Report on BPMC
Blueprint Medicines Stock Down 0.5 %
BPMC traded down $0.43 on Thursday, hitting $86.69. The company had a trading volume of 632,925 shares, compared to its average volume of 1,012,945. The stock has a fifty day moving average price of $99.38 and a 200-day moving average price of $94.16. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85. Blueprint Medicines has a 12-month low of $80.68 and a 12-month high of $121.90. The stock has a market capitalization of $5.54 billion, a price-to-earnings ratio of -80.27 and a beta of 0.58.
Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%.
Institutional Trading of Blueprint Medicines
A number of institutional investors have recently bought and sold shares of BPMC. Quarry LP acquired a new stake in shares of Blueprint Medicines in the 3rd quarter worth about $32,000. R Squared Ltd bought a new position in shares of Blueprint Medicines in the fourth quarter worth $51,000. Covestor Ltd boosted its holdings in Blueprint Medicines by 206.7% in the 3rd quarter. Covestor Ltd now owns 598 shares of the biotechnology company's stock valued at $55,000 after purchasing an additional 403 shares during the period. Headlands Technologies LLC purchased a new position in Blueprint Medicines during the fourth quarter worth about $65,000. Finally, Thematics Asset Management bought a new stake in Blueprint Medicines during the fourth quarter valued at approximately $72,000.
Insider Activity
In related news, COO Christina Rossi sold 2,274 shares of the stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $95.91, for a total transaction of $218,099.34. Following the sale, the chief operating officer now owns 69,383 shares of the company's stock, valued at $6,654,523.53. This represents a 3.17 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Ariel Hurley sold 1,819 shares of the company's stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $93.26, for a total transaction of $169,639.94. Following the transaction, the insider now owns 14,967 shares of the company's stock, valued at approximately $1,395,822.42. This represents a 10.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 48,427 shares of company stock valued at $4,837,801 in the last quarter. Company insiders own 4.21% of the company's stock.
About Blueprint Medicines
(
Get Free Report)
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
Read More
Before you consider Blueprint Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Blueprint Medicines wasn't on the list.
While Blueprint Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
